# Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer

> **NCT05377047** · NA · RECRUITING · sponsor: **Vastra Gotaland Region** · enrollment: 345 (estimated)

## Conditions studied

- Breast Cancer Stage IV
- Oligometastatic Disease

## Interventions

- **RADIATION:** SABR

## Key facts

- **NCT ID:** NCT05377047
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-19
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 345 (ESTIMATED)
- **Last updated:** 2022-10-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05377047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05377047, "Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05377047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*